Enzymotec Ltd. (ENZY) Upgraded at Zacks Investment Research
According to Zacks, “Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. “
Separately, Jefferies Group reaffirmed a hold rating on shares of Enzymotec in a research report on Thursday, August 4th.
Shares of Enzymotec (NASDAQ:ENZY) opened at 7.33 on Tuesday. The firm has a 50-day moving average price of $7.23 and a 200-day moving average price of $8.10. The stock has a market cap of $166.53 million, a price-to-earnings ratio of 38.58 and a beta of 1.27. Enzymotec has a 12 month low of $6.60 and a 12 month high of $10.32.
Enzymotec (NASDAQ:ENZY) last announced its quarterly earnings data on Tuesday, August 9th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by $0.04. The firm earned $15 million during the quarter, compared to the consensus estimate of $14.90 million. Enzymotec had a return on equity of 3.12% and a net margin of 8.37%. The firm’s revenue for the quarter was down 12.7% compared to the same quarter last year. During the same period last year, the company earned $0.11 EPS. Equities analysts expect that Enzymotec will post $0.27 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Van ECK Associates Corp raised its stake in shares of Enzymotec by 5.9% in the second quarter. Van ECK Associates Corp now owns 12,659 shares of the company’s stock worth $106,000 after buying an additional 706 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its position in Enzymotec by 12.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 21,313 shares of the company’s stock valued at $178,000 after buying an additional 2,298 shares in the last quarter. Menta Capital LLC increased its position in Enzymotec by 12.4% in the second quarter. Menta Capital LLC now owns 48,488 shares of the company’s stock valued at $405,000 after buying an additional 5,362 shares in the last quarter. State of New Jersey Common Pension Fund D increased its position in Enzymotec by 68.0% in the second quarter. State of New Jersey Common Pension Fund D now owns 22,021 shares of the company’s stock valued at $184,000 after buying an additional 8,915 shares in the last quarter. Finally, Public Employees Retirement System of Ohio increased its position in Enzymotec by 48.6% in the second quarter. Public Employees Retirement System of Ohio now owns 35,187 shares of the company’s stock valued at $294,000 after buying an additional 11,501 shares in the last quarter. Institutional investors and hedge funds own 36.20% of the company’s stock.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.